VivoSeq
Oncology

Recurrent Ovarian Epithelial Cancer

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Recurrent Ovarian Epithelial Cancer is an early-stage landscape with 0 programs across 1 company. The most active players are Gynecologic Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed9 · 90%
Unknown status1 · 10%

Clinical Trials

Trial Activity

10 trials

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00617188·26 enrolled
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00022659·64 enrolled
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed·GGynecologic Oncology Group·Phase 2·NCT00407758·28 enrolled
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Completed·NNCIC Clinical Trials Group·Phase 2·NCT00010179·81 enrolled
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed·GGynecologic Oncology Group·Phase 2·NCT00054119·27 enrolled
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
Completed·—·Phase 1·NCT02275039·12 enrolled
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00023712·58 enrolled
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed·GGynecologic Oncology Group·Phase 2·NCT00086892
Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer
Completed·—·Phase 1/2·NCT00004177·15 enrolled
Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
Unknown status·HHospices Civils de Lyon·Phase 3·NCT03220932·132 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)